MARKET

AGIO

AGIO

Agios
NASDAQ

Real-time Quotes | Nasdaq Last Sale

55.72
+0.50
+0.91%
After Hours: 55.04 -0.68 -1.22% 16:45 05/17 EDT
OPEN
54.96
PREV CLOSE
55.22
HIGH
56.29
LOW
54.02
VOLUME
389.44K
TURNOVER
--
52 WEEK HIGH
58.93
52 WEEK LOW
32.47
MARKET CAP
3.43B
P/E (TTM)
-10.2051
1D
5D
1M
3M
1Y
5Y
Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress
GlobeNewswire · 5d ago
10 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson
In this article we will take a look at the 10 best pharmaceutical stocks to buy according to billionaire Kerr Neilson. You can skip our detailed analysis of the pharmaceutical industry’s outlook for 2021 and some of the major growth catalysts for pharmaceu...
Insider Monkey · 5d ago
Cancer Biopharmaceuticals Market Share, Growth, Size, Global Industry Trends, Industry Analysis, Segments, COVID-19 Impact, Emerging Technologies, Opportunity and Forecast 2021 to 2028
May 10, 2021 (Market Insight Reports) -- “Cancer Biopharmaceuticals Market (US, Europe, Asia-Pacific) 2021 Global Industry Market research report gives key...
Market Insight Reports · 05/10 18:04
Relapsed Acute Myeloid Leukemia Drug Market 2021: Comprehensive Size Analysis, In-depth Research on Market Share, Growth Factors, Regions, Business Plans, with Development Status till 2027
May 07, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Our Latest Report on “Relapsed Acute...
The Express Wire · 05/07 05:24
Agios Pharma (AGIO) Gets a Hold Rating from Leerink Partners
Leerink Partners analyst Andrew Berens reiterated a Hold rating on Agios Pharma (AGIO) on April 29 and set a price target of $50.00. The company's shares
SmarterAnalyst · 05/03 11:50
Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress
Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.
Zacks · 04/30 12:46
--Canaccord Genuity Adjusts Price Target on Agios Pharmaceuticals to $65 From $57, Maintains Buy Rating
MT Newswires · 04/30 12:17
Canaccord Genuity Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $65
Canaccord Genuity maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $57 to $65.
Benzinga · 04/30 12:14
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGIO. Analyze the recent business situations of Agios through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGIO stock price target is 63.50 with a high estimate of 76.00 and a low estimate of 50.00.
EPS
Institutional Holdings
Institutions: 277
Institutional Holdings: 74.37M
% Owned: 120.78%
Shares Outstanding: 61.57M
TypeInstitutionsShares
Increased
36
6.18M
New
10
90.65K
Decreased
43
896.23K
Sold Out
25
1.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Director
David Schenkein
Chief Executive Officer/Director
Jacqualyn Fouse
Chief Financial Officer
Jonathan Biller
Senior Vice President/General Manager
Orlando Oliveira
Chief Scientific Officer
Bruce Car
Other
Christopher Bowden
Other
Darrin Miles
Lead Director/Independent Director
John Maraganore
Independent Director
Paul Clancy
Independent Director
Ian Clark
Independent Director
Kaye Foster
Independent Director
Maykin Ho
Independent Director
David Scadden
Independent Director
Kaye Foster-Cheek
No Data
  • All
  • Financials
  • Insiders
More
About AGIO
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias. The Company’s clinical candidate, mitapivat, is in Phase III studies which is developed for the treatment of pyruvate kinase (PK), deficiency, thalassemia, and sickle cell disease (SCD). The Company is also developing AG-946, a clinical-stage, next-generation oral activator of pyruvate kinase R (PKR) enzymes, which is in Phase I clinical study. The mitapivat is an orally available small molecule and a potent activator of the PKR enzymes.

Webull offers kinds of Agios Pharmaceuticals Inc stock information, including NASDAQ:AGIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGIO stock methods without spending real money on the virtual paper trading platform.